{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:31:09Z","timestamp":1783074669248,"version":"3.54.6"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.urolonc.2020.07.010","type":"journal-article","created":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T01:43:59Z","timestamp":1598492639000},"page":"73.e9-73.e18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of the clinical use of PET\/CT with 68Ga-PSMA for the assessment of biochemical recurrence of low or intermediate-risk prostate cancer"],"prefix":"10.1016","volume":"39","author":[{"given":"Andr\u00e9 Marcondes Braga","family":"Ribeiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo N\u00f3brega Pereira","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00eanio de C\u00e1ssio","family":"Zequi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2020.07.010_bib0001","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA"},{"key":"10.1016\/j.urolonc.2020.07.010_bib0002","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"71","author":"Mottet","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.07.010_bib0003","doi-asserted-by":"crossref","unstructured":"D'Amico A v, Whittington R, Malkowicz SB, Fondurulia J, Chen MH, Kaplan I, et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol1999;17:168\u201372. https:\/\/doi.org\/10.1200\/JCO.1999.17.1.168.","DOI":"10.1200\/JCO.1999.17.1.168"},{"key":"10.1016\/j.urolonc.2020.07.010_bib0004","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system","volume":"40","author":"Epstein","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.urolonc.2020.07.010_bib0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00259-018-4066-4","article-title":"68Ga-PSMA-11 PET\/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng\/ml. Efficacy and impact on treatment strategy","volume":"46","author":"Farolfi","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.urolonc.2020.07.010_bib0006","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s00259-017-3711-7","article-title":"Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET\/CT in patients with recurrent prostate cancer: evaluation in 1007 patients","volume":"44","author":"Afshar-Oromieh","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.urolonc.2020.07.010_bib0007","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00259-018-4189-7","article-title":"68Ga-PSMA-11 PET\/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy","volume":"46","author":"Ceci","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.urolonc.2020.07.010_bib0008","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1007\/s00259-015-3078-6","article-title":"(68)Ga-PSMA PET\/CT for restaging recurrent prostate cancer: which factors are associated with PET\/CT detection rate?","volume":"42","author":"Ceci","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.urolonc.2020.07.010_bib0009","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2967\/jnumed.115.154153","article-title":"Evaluation of hybrid 68Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy","volume":"56","author":"Eiber","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.urolonc.2020.07.010_bib0010","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00259-015-3240-1","article-title":"Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET\/CT in relation to PSA levels, PSA doubling time and Gleason score","volume":"43","author":"Verburg","year":"2016","journal-title":"Eur J NuclMed Mol Imaging"},{"key":"10.1016\/j.urolonc.2020.07.010_bib0011","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.2967\/jnumed.117.196683","article-title":"Treatment outcomes from 68Ga-PSMA PET\/CT-informed salvage radiation treatment in men with rising PSA after radical prostatectomy: prognostic value of a negative PSMA PET","volume":"58","author":"Emmett","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.urolonc.2020.07.010_bib0012","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/bju.13739","article-title":"Clinical impact of 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography\/computed tomography (PET\/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis","volume":"120","author":"Albisinni","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2020.07.010_bib0013","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00259-018-4249-z","article-title":"Impact of Ga-68-PSMA PET\/CT on management in prostate cancer patients with very early biochemical recurrence after radical prostatectomy","volume":"46","author":"Bashir","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.urolonc.2020.07.010_bib0014","series-title":"Presented at the EAU Annual Congress","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer","author":"Mottet","year":"2019"},{"key":"10.1016\/j.urolonc.2020.07.010_bib0015","series-title":"Presented at the EAU Annual Congress","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer","author":"Mottet","year":"2020"},{"key":"10.1016\/j.urolonc.2020.07.010_bib0016","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S1470-2045(18)30571-0","article-title":"Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group","volume":"19","author":"Lecouvet","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2020.07.010_bib0017","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","article-title":"The diagnostic value of PET\/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer","volume":"42","author":"Afshar-Oromieh","year":"2015","journal-title":"Eur J Nucl MedMol Imaging"},{"key":"10.1016\/j.urolonc.2020.07.010_bib0018","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/bju.13397","article-title":"68Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment","volume":"117","author":"van Leeuwen","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2020.07.010_bib0019","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2967\/jnumed.117.192625","article-title":"Impact of 68Ga-prostate-specific membrane antigen PET\/CT on prostate cancer management","volume":"59","author":"Afaq","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.urolonc.2020.07.010_bib0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0360-3016(03)01442-1","article-title":"Is there a favorable subset of patients with prostate cancer who develop oligometastases?","volume":"58","author":"Singh","year":"2004","journal-title":"Int J Radiat Oncolog Biol Phys"},{"key":"10.1016\/j.urolonc.2020.07.010_bib0021","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.eururo.2014.03.019","article-title":"Contemporary role of salvage lymphadenectomy in patients with recurrence following radical prostatectomy","volume":"67","author":"Abdollah","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.07.010_bib0022","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.eururo.2015.07.004","article-title":"Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis","volume":"69","author":"Ost","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.07.010_bib0023","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1200\/EDBK_159241","article-title":"Approach to oligometastatic prostate cancer","volume":"35","author":"Bernard","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annual Meeting"},{"key":"10.1016\/j.urolonc.2020.07.010_bib0024","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13550-016-0233-4","article-title":"Impact of 68Ga-PSMA PET\/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy","volume":"6","author":"Bluemel","year":"2016","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.urolonc.2020.07.010_bib0025","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7150\/thno.7447","article-title":"Prospective of 68Ga-radiopharmaceutical development","volume":"4","author":"Velikyan","year":"2013","journal-title":"Theranostics"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920303331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920303331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:19:32Z","timestamp":1761041972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143920303331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1078143920303331"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.07.010","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the clinical use of PET\/CT with 68Ga-PSMA for the assessment of biochemical recurrence of low or intermediate-risk prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}